Floatz logo

Nivestim

Acute Monocytic Leukemia

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universityprotein_peptidePhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Acute Monocytic Leukemia cohort.

Asset / SponsorPhaseRating
Etoposide
Stanford University
Phase 3BBB
Cytarabine
Chinese PLA General Hospital
Phase 3BBB
Daunomycin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
ECOG-ACRIN Cancer Research Group
Phase 3BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB

View all 49 →

Same molecule, other indications

Nivestim is also rated in:

Burkitt lymphomaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
neutropeniaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →